Diurnal’s Swiss Partner Submits MAA for Alkindi to Swissmedic

News
Article

The Swiss marketing and distribution partner of Diurnal Group, EffRx Pharmaceuticals, has submitted a MAA for Alkindi to Swissmedic.

The Swiss marketing and distribution partner of Diurnal Group, EffRx Pharmaceuticals, has submitted a marketing authorization application (MAA) for Alkindi to the Swiss regulatory body, Swissmedic.Alkindi

According to an Oct. 21, 2020 press release, the MAA has been based on the European regulatory dossier and published clinical trial data on Alkindi—hydrocortisone granules in capsules for opening. EffRx anticipates a potential market launch for Alkindi in Switzerland by 2022 and will receive the exclusive rights to market and sell the product in Switzerland once the product has been registered.

“We are pleased to see the submission of a MAA for Alkindi in Switzerland by EffRx,” said Martin Whitaker, CEO of Diurnal, in the press release. “[This] announcement is yet further validation of the quality of our products and broadens the future availability of Alkindi outside our core markets in line with our global strategy. We look forward to working with EffRx to make Alkindi available to patients suffering from pediatric adrenal insufficiency (AI) in Switzerland.”

Alkindi is already approved and marketed in Europe and is the first preparation of hydrocortisone that has been specifically designed for pediatric use in the treatment of AI and the related condition, congenital adrenal hyperplasia.

Source: Diurnal

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes